Ocular Therapeutix, Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 9, 2026, to register an additional 1,000,000 shares of common stock issuable under its 2019 Inducement Stock Incentive Plan, as amended.

Key Highlights

  • Shares registered: 1,000,000 shares of common stock, $0.0001 par value per share, under the 2019 Inducement Stock Incentive Plan, as amended.
  • Plan covered: The 2019 Inducement Stock Incentive Plan, which has been amended at least six times according to the filing.
  • Prior registrations incorporated: The filing incorporates by reference six previously effective Form S-8 registration statements filed between March 12, 2020, and February 5, 2026.
  • Filer classification: Ocular Therapeutix is classified as a large accelerated filer in this filing.
  • Signing officer: Pravin U. Dugel, M.D., Executive Chairman, President and Chief Executive Officer, signed the registration statement on November 9, 2026.
  • Legal opinion: Wilmer Cutler Pickering Hale and Dorr LLP provided the opinion of counsel included as Exhibit 5.1.

Ocular Therapeutix Adds Shares to 2019 Inducement Plan via New S-8 Filing

According to the filing, Ocular Therapeutix, Inc. (NASDAQ:OCUL) submitted a Form S-8 registration statement on November 9, 2026, to register 1,000,000 additional shares of common stock, par value $0.0001 per share, issuable under the company's 2019 Inducement Stock Incentive Plan, as amended (the "2019 Inducement Plan"). The filing states that this registration is "for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective."

The filing incorporates by reference the contents of six prior Form S-8 registration statements. Those earlier filings were made on March 12, 2020 (File No. 333-237115); March 11, 2021 (File No. 333-254143); February 22, 2024 (File No. 333-277244); May 7, 2024 (File No. 333-279176); November 14, 2024 (File No. 333-283215); and February 5, 2026 (File No. 333-293220). The company also noted a Post-Effective Amendment No. 1 to two of those earlier registration statements, filed on August 9, 2021.

The 2019 Inducement Plan, as reflected in the exhibits listed in the filing, has been amended six times, with the most recent amendment, Amendment No. 6, filed as Exhibit 10.1 to the company's Quarterly Report on Form 10-Q on November 9, 2026. PricewaterhouseCoopers LLP provided its consent as the company's independent registered public accounting firm, listed as Exhibit 23.2. The registration statement was signed by Pravin U. Dugel, M.D. as principal executive officer and Jason S. Robins as principal financial and accounting officer, along with seven directors.

What Was Disclosed

Ocular Therapeutix filed a Form S-8 on November 9, 2026, registering 1,000,000 additional shares of common stock under its 2019 Inducement Stock Incentive Plan, as amended, incorporating by reference six prior S-8 filings dating back to 2020.